ArticleClinical case reports2025
Coexistence of Localized and Systemic Juvenile Scleroderma: A Case Report and Review of Literature.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coexistence of Localized and Systemic Juvenile Scleroderma: A Case Report and Review of Literature.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile scleroderma (JS) is a rare chronic connective tissue disorder characterized by progressive fibrosis of the skin and soft tissues with/without internal organ involvements. Scleroderma manifests itself in both systemic (SSc) and localized (LS) forms. This case report aimed to present an Iranian girl with coexistence of SSc and LS treated by Tocilizumab. A 12-year-old girl was referred to the rheumatology clinic with the chief complaint of asymmetrical facial appearance starting from two years ago and coexisting with restricted phalangeal motion for the last 6 months. In the physical examination, she had left hemi-facial atrophy as well as stiffness, swelling, redness, shiny appearance of the skin of hands and feet, and phalangeal joints restriction. Diagnostic assessments, including relevant consultations and laboratory tests, showed nothing important except for slightly elevated erythrocyte sedimentation rate (ESR), C reactive protein (CRP), and antinuclear antibody (ANA) titer of 1/80. At first, the therapeutic intervention consisted of methotrexate, Cellcept, and low dose prednisolone. Because of the unsatisfactory response, pulse dose of methylprednisolone was added. Due to incomplete therapeutic response, intravenous (IV) Tocilizumab was administered for at least 6 months, which resulted in significant improvement, notably in facial morphea. This case report emphasized the importance of accurate and early diagnosis and tailored therapeutic interventions in JS. In patients with LS, attention should be paid to rule out the overlap of systemic and localized types to prevent treatment delay. The presence of Raynaud's phenomenon, telangiectasia, or ANA positivity in a patient with LS should alert the physician to consider the possible coexistence of SSc and LS. Pulse dose of methylprednisolone is the mainstay of treatment in LS. Considering the risk of renal crisis, corticosteroids might be administered cautiously in SSc with frequent monitoring of electrolytes and renal function. Notably, Tocilizumab can be used as a pivotal therapeutic option in managing refractory morphea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.